Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in Primary Immunodeficiency Diseases (PIDD)

NCT05755035 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT05755035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05755035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in Primary Immunodeficiency Diseases (PIDD)
Lead sponsor
Takeda
Phase
Phase 2/3
Overall status
Completed
Start date
October 24, 2023
Completion date
January 20, 2026
Enrollment
65 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

primary immunodeficiency diseases (pid)